Videos |View More
Meet the Team: Kenan Onel, MD, PhD
Ken Onel, MD, PhD, is driven by a deep passion for learning how the body develops cancer and what can be done to prevent it.
VHL Syndrome Q&A with Roswell Park Comprehensive Cancer Center
VHL (von Hippel-Lindau disease) is a rare genetic disease that can cause tumors, both benign and malignant, to develop in up to ten different organs throughout a patient's life.
Anthony Dakwar, MD, Assistant Professor of Oncology at Roswell Park, discusses the unique challenges that young adult colorectal cancer cases present to primary care physicians and oncologists and why a comprehensive cancer center like ...
Coordination of Cancer Care Along with Managing Comorbidities
Primary care doctors are more than capable of caring for cancer survivors, but they need to stay informed on what cancer treatments their patients have received and their potential side effects.
Cancer occurrence is on the rise in young adults and is often diagnosed at a late stage. Denise Rokitka, MD, MPH, Director of the Young Adult Program and Oncofertility Program at Roswell Park Comprehensive Cancer Center, discusses how ...
Warning Signs of Hematologic Malignancies in the Primary Care Setting
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, offers guidance on what red flags may indicate a hematologic cancer in your patients to help you identify these complex and often difficult-to-treat ...
Screening for Cancer Survivors
Mary Reid, MSPH,PhD, shares the recurrence rate of cancers and the importance of getting screened. Reid also shares how essential it is for primary care physicians for being up to date on cancer screening guidelines as they are the first ...
Caring for Cancer Survivors: Creating a Care Plan
In part one of a two-part series, Dr. Mary Reid discusses common issues faced by cancer survivors post-treatment.
Roswell Park | Ranked 14th on List of Nation’s Best Hospitals for Cancer
Roswell Park is proud to be ranked as a top cancer hospital by U.S. News and World Report. We moved up to number 14 out of nearly 900 on the 2019-2020 Best Hospitals for Cancer list — putting us in the top 1.5% of cancer hospitals nationwide.
Medical Cannabis for the Cancer Patient
There's a lot of hype about the benefits of medical cannabis, but how do you, as a healthcare provider, sort fact from fiction and answer questions from your patients? A panel of experts discuss the use of medical cannabis by the cancer ...
Pathways in Oncology: Tools to Ensure Quality Care
Stephen Edge, MD, FACS, FASCO, discusses the benefits of using clinical oncology pathways, including how to select the primary choice for treatment when using pathways.
Supportive and Palliative Care for the Primary Care Physician
Amy Case, MD reviews the differences between supportive and pallative care, and hospice care.
How to Choose the Best Cancer Surgeon for Your Patients
Khurshid Guru, MD, Chair, Department of Urology and Director, Robotic Surgery, at Roswell Park Comprehensive Cancer Center offers advice about referring patients to the right cancer surgery center and explains how to measure the quality ...
The Impact of Cancer on the Young Adult Patient
Dr. Denise Rokitka analyzes the decrease in survival rate for AYA, and the contributing factors associated with this alarming trend.
News |View More
Roswell Park, Ellis Medicine Partner to Expand Access to Cancer Care in the Capital Region
Ellis is creating a medical oncology/chemotherapy/infusion center at the hospital—and through the affiliation, will expand local access to the services of Roswell Park, the only National Cancer Institute (NCI)-designated comprehensive ...
Governor Kathy Hochul today celebrated the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, New York's first cell and gene therapy hub, located at Roswell Park Comprehensive Cancer Center in Buffalo.
Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.
This site is intended for healthcare professionals